| Article Access Statistics|
| Viewed||6961 |
| Printed||103 |
| Emailed||4 |
| PDF Downloaded||780 |
| Comments ||[Add] |
| Cited by others ||2 |
Click on image for details.
|Year : 2007
: 49 | Issue : 4 | Page
|Clozapine: Current perspective
Ram K Solanki, Paramjeet Singh, Mukesh K Swami
Psychiatry Center, Department of Psychiatry, SMS Medical College, Jaipur, India
Click here for correspondence address and
| Abstract|| |
The author conducted a review of studies that compared the efficacy, tolerability and indication for the use of clozapine in current perspectives for the treatment of resistant schizophrenia/ partial responders.
Keywords: Clozapine, resistant schizophrenia, SGA
|How to cite this article:|
Solanki RK, Singh P, Swami MK. Clozapine: Current perspective. Indian J Psychiatry 2007;49:271-6
| Introduction|| |
In the early 1960s, German psychiatrists working with G. Stille at Wander Pharmaceuticals in Bern, Switzerland, worked to refute the concept that EPS and antipsychotic efficacy were linked.  Their work led to the introduction of clozapine, an antipsychotic with no EPS or minimally associated EPS. , Clinical confirmation of this profile for clozapine was provided in open studies by Austrian  and German  investigators in 1966 and later by Swiss researchers  in a double-blind study in 1971. Clozapine was briefly marketed and quickly withdrawn. 
However, enthusiasm for the drug was maintained by a small cadre of clinical investigators including G. Honigfeld at Sandoz, who observed that clozapine, was remarkably effective in treatment-resistant patients. This led to a landmark double-blind study of clozapine in a well-defined group of treatment-resistant patients whose blood cell counts were closely monitored during treatment  and ultimately to its introduction to the US market in 1990. Clozapine was approved by the FDA in 1990. , Clozapine was also approved for reducing the risk of suicide in schizophrenic or schizoaffective patients judged to be at chronic risk for suicidal behavior in December 2002.
Mode of action
The mechanisms of action which account for the effectiveness of clozapine as a pharmacotherapy for the treatment of neuroleptic non-responders and neuroleptic intolerant schizophrenic subjects remain elusive. It is characterized by generally lower affinities for D2 receptors and relatively greater affinities for serotonin (5-hydroxytryptamine) 5-HT2A receptors in particular, but also for noradrenergic receptors (α1 and α2), muscarinic acetylcholine receptors, histamine and other dopamine (DA) subtype receptors.
Tauscher et al,  used Positron emission tomography with the radioligands [ 11 C] SCH23390 and [ 11 C]raclopride to investigate D 1 and D 2 receptor occupancy in vivo in 25 schizophrenic patients receiving atypical antipsychotic treatment with clozapine, olanzapine, quetiapine or risperidone. They concluded that among the atypical antipsychotics, clozapine appeared to have a simultaneous and equivalent occupancy of dopamine D 1 and D 2 receptors. Whether its effect on D 1 receptors represents agonism or antagonism is not yet clear. This issue is still unresolved in the preclinical arena. The distinctive effect on D 1 /D 2 receptors may be responsible for clozapine's unique effectiveness in patients with schizophrenia refractory to other typical and atypical antipsychotics.
Meta analysis of controlled trials involving patients who had treatment resistant schizophrenia ,,, and a systemic review  showed that clozapine is as effective or is more effective than the other second generation antipsychotics for treating treatment resistant schizophrenia.
In an open trial by Agarwal et al.,  drug-resistant schizophrenics were treated with clozapine for sixteen weeks. The patients were rated on BPRS, PANSS, Side effects scale and Global Impression Scale at weeks 0, 9 and 16. A battery of base-line investigations was done and hemogram was repeated at weekly intervals. Of the total 29 patients included, 25 completed the trial. The patients showed significant improvement on both BPRS and PANSS, though the improvement was more in initial weeks than between 9 and 16 weeks. The most common side effects observed were sedation, hypersalivation and tachycardia.
Moncrieff  compared clozapine with conventional antipsychotics and challenged previous results, criticizing methodological bias in the clinical trials. He found that recent large-scale studies have not found a substantial advantage for clozapine, especially in terms of a clinically relevant effect. Meta-regression showed that shorter study duration, financial support from a drug company and higher baseline symptom score consistently predicted greater advantage of clozapine. He concluded that the superiority of clozapine over conventional antipsychotic drugs has not been consistently and conclusively demonstrated. There is substantial variation between results of different studies, which appears to be accounted for by study duration and funding and level of initial symptoms. Clozapine's greatest advantage relative to standard medication may be seen in patients with very high levels of initial symptoms.
Several authors have questioned whether clozapine should be indicated as a first-line treatment for early psychosis. ,, The risk-benefit ratio has been reappraised  in view of the lower rates of relapse, hospitalization, extrapyramidal symptoms and suicidality and the improvements in negative symptoms, cognition and social functioning associated with clozapine.
Woerner et al., reported the interesting observation that clozapine, in comparison with fluphenazine, was similarly efficacious for new-onset patients with schizophrenia or schizoaffective disorder.  It is frequently questioned, why is clozapine, compared with typical antipsychotics, dramatically more efficacious for treatment-resistant psychosis but merely similarly efficacious for new-onset schizophrenia? To provide an explanation it is hypothesized  that patients taking long-term neuroleptic medication experience upregulation of dopamine D 2 receptors in their brains. Typical antipsychotics may cause the upregulation because they dissociate slowly from the D 2 receptor  and the neurons respond by trying to overcome the chronic blockade. In contrast, clozapine, which is a fast dissociator,  may allow endogenous dopamine to activate the receptor enough to avoid the problem of upregulation. In addition to dopaminergic upregulation in the nigrostriatal tracts (thought to underlie the pathophysiology of tardive dyskinesia), many investigators have suggested that dopaminergic upregulation may occur in mesolimbic or mesocortical tracts, leading to a worsening of psychosis beyond the original level. This phenomenon has been called "tardive psychosis" or "supersensitivity psychosis".  Because increasing the dose of the neuroleptic eventually will make the problem worse, tardive psychosis may be a major form of treatment-resistant psychosis. Clozapine, in comparison with typical antipsychotics, may be more efficacious for treatment-resistant psychosis because it allows the reversal of the dopaminergic upregulation in the mesolimbic or mesocortical tracts, leading to an improvement in tardive psychosis. On the other hand, clozapine, in comparison with typical antipsychotics, may not be more efficacious for new-onset schizophrenia because these patients have not been medicated previously and do not have dopaminergic upregulation that can be reversed. 
Pragmatic trials, supposed to provide more complete information for physician in clinical practice,  support the effectiveness of clozapine over newer atypical antipsychotics. Evoy et al.,  in a phase 2 trial in the CATIE study,  studied 99 patients who had not responded to atypical antipsychotics in previous phase.  Patients are randomly assigned to open label clozapine (n=49) or to blind treatment with another SGA (olanzapine, n=19; quitiapine, n=15; risperidone, n=16). When compared with other SGA's, clozapine had the greatest reduction in the PANSS total score and lowest discontinuation rates; that is the use of clozapine proved to be more effective than switching to another second generation antipsychotic in patients who previously had not responded to another second generation antipsychotics.
In another pragmatic trial Lewis et al,  studied 137 patients who had schizophrenia and who had showed a poor response to 2 or more antipsychotics.. The patients were assigned randomly to receive clozapine (n=67) or a second generation antipsychotics (risperidone, olanzapine, quetiapine, amisulpride). At the end of 1 year patients who received clozapine showed a reduction in psychopathology and improved quality of life.
In a Meta analysis comparing clozapine with a second generation antipsychotic, Tuunainen et al,  found a trend for clozapine to be more effective in improving positive symptoms but not negative symptoms; no difference were seen in other outcome variables, such as relapse rates or global improvement. There was a trend for a second generation antipsychotics to be more effective in improving cognition.
In a Double-Blind Comparative Study,  including 273 patients with poor previous treatment response, Azorin et al., found that the magnitude of improvement in mean BPRS and CGI scores from baseline to end of the study was significantly greater in the clozapine group than in the risperidone group. Statistically significant differences in favor of clozapine were also seen for most of the secondary efficacy measures (Positive and Negative Syndrome Scale, Calgary Depression Scale, Psychotic Depression Scale and Psychotic Anxiety Scale). The adverse event profile was similar for both treatment groups, with a lower risk of extrapyramidal symptoms in the clozapine group.
Clozapine has shown consistent clinical benefit in schizophrenic patient with persistent aggressive and violent behavior. , Whether this is due to a sedative effect, a specific antiaggressive action or just reflects an overall improvement in psychosis is unknown.
McGurk et al.,  investigated the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia. Spatial working memory performance was evaluated at baseline and after 17 and 29 weeks in 97 patients with schizophrenia participating in a multisite trial. They found that compared with baseline performance while receiving conventional antipsychotic medication, risperidone improved and clozapine worsened, spatial working memory performance. The differential effects of these medications on spatial working memory may be due to the anticholinergic effects of clozapine and prefrontal dopamine-enhancing effects of risperidone.
Bilder et al.,  examined the effects of clozapine, olanzapine, risperidone and haloperidol on 16 measures of neurocognitive functioning in a double-blind, 14-week trial involving 101 patients. A global score was computed along with scores in four neurocognitive domains: memory, attention, motor function and general executive and perceptual organization. They found that global neurocognitive function improved with olanzapine and risperidone treatment and these improvements were superior to those seen with haloperidol. Patients treated with olanzapine exhibited improvement in the general and attention domains but not more than that observed with other treatments. Patients treated with risperidone exhibited improvement in memory that was superior to that of both clozapine and haloperidol. Clozapine yielded improvement in motor function but not more than in other groups.
Purdon et al.,  examined Neuropsychological change after 6 weeks of clozapine treatment in 18 treatment-refractory patients to test anticipated domain-specific cognitive improvements. The results showed that the comprehensive neuropsychological test battery was sensitive to general cognitive changes with clozapine and supported the hypothesized domain-specific gains on tests of motor and mental speed, visual spatial manipulation and new verbal learning. Novel gains were also apparent on tests of new learning with nonverbal material.
It is estimated that approximately 30% of patients treated with clozapine do not respond adequately, remaining with persistent psychotic symptoms despite taking adequate treatment for sufficient period. Such patients are called "partial responders to clozapine," "clozapine resistant," or even "super refractory".  Despite lack of evidence augmentation strategies are used in such patients. Various antipsychotics have been used to augment clozapine: risperidone, , amisulpride, , aripiprazole,  haloperidol,  loxapine,  olanzapine,  pimozide  and ziprasidone.  The benefits of such augmentation strategies remain inconclusive because they were tested in case series or case reports, which have a low strength of evidence as compared with controlled trials. ,
In a study conducted at psychiatry center, S.M.S. medical college, Jaipur, by Dr. R.K. Solanki and Dr. Paramjeet Singh, 100 diagnosed cases of schizophrenia on clozapine maintenance (not showing adequate response) were augmented with risperidone (2-4 mg/d). Patients showed significant improvement after 4 week on CGI, BPRS and PANSS scales.
Other therapeutic uses
Lieberman et al.,  reviewed eight published studies that describe clozapine's effects on tardive dyskinesia and examined the outcome of 30 patients with tardive dyskinesia treated with clozapine for up to 36 months. They found that tardive dyskinesia response to clozapine is variable but that approximately 43% of cases, particularly those with dystonic features, improved after clozapine treatment.
In international suicide prevention trial  including 980 patients from 67 medical centers in 11 countries (assigned randomly to either treatment with clozapine or olanzapine) it is concluded that the rate of suicidal behavior or suicide attempts are significantly lower in patient taking clozapine than in those taking olanzapine, although the rates of deaths from suicide were not significantly different between groups.
Turetz et al.,  treated 11 neuroleptic-resistant children (< 13 years) with schizophrenia in an open trial. The mean clozapine dosage was 227.3 mg. There was an overall statistically significant reduction in all parameters, especially positive symptoms, implying a favorable outcome. Most of the improvement occurred during the first 6 to 8 weeks. The major side-effects were somnolence and drooling (no agranulocytosis).
Green et al.,  examined efficacy of clozapine in a group of patients (n=22) with treatment-refractory bipolar disorder, manic type with psychotic features and suggested that clozapine is an effective agent for patients with treatment-refractory psychotic mania. Similar results are reported previously by Calabrese et al.  It is also suggested that clozapine could be efficient in psychotic refractory depression. 
Clozapine is least likely to worsen the neurological disorder  so it is preferred in psychotic patient with Parkinson disease. Some neurologists even consider clozapine to be an antipsychotics of choice in these patients. 
Predictors of response
A number of authors have investigated the factors associated with response to clozapine but findings are contradictory. Reviewing the evidence Chung and Remington  suggested that as yet there are no predictors of response to clozapine; rather there are markers. The reduction in frontal cortex metabolism seen with positron mission tomography, the reduction in caudate volume seen with MRI, the baseline severity of psychopathology and plasma clozapine level can not be considered predictors of response because of inconsistency of data.
Side effect profile
Apart from common side effects like sedation, dizziness, syncope, tachycardia, hypotension, ECG changes, nausea and vomiting, fatigue, weight gain, constipation, anticholinergic effects and subjective muscle weakness, several rare side effects has been described during clozapine treatment. One most important is neutropenia which may lead to fatal agranulocytosis, occurs in about 1% patient. Its mechanism is unclear but may be the result of direct toxicity or an immune response.  Annan LJA and Andrews CD  investigated the results of a rechallenge in 53 patients who has previously experienced leucopenia or neutropenia during clozapine therapy. Of 53 patients who were rechallenged, 20 (38%) experienced a further blood dyscrasia. In 17 of these 20 patients (85%) the second blood dyscrasia was more severe (P<0.001), in 12 (60%) it lasted longer (P=0.0368) and in 17 (85%) it occurred more quickly on rechallenge (P<0.001).they concluded that after risks and benefits have been considered, rechallenge may well be justified in some patients.
In a review Wetterling suggested that Average weight gain with clozapine is 1.72 kg /month, occurring most frequently during first 6 to 12 month of treatment.  There have been also reports of glucose intolerance during clozapine treatment.
In a 5 year naturalistic study Henderson et al.,  examined the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose and treatment with Valproate. Mean age at the time of clozapine initiation of the 82 patients was 36.4 years. The mean baseline weight was 175.5 lb and the mean body mass index was 26.9 kg/m 2 . Thirty patients (36.6%) were diagnosed with diabetes during the 5-year follow-up. Weight gain, use of Valproate and total daily dose of clozapine were not significant risk factors for developing diabetes mellitus. Patients experienced significant weight gain that continued until approximately month 46 from initiation of clozapine. There was a nonsignificant increase in total serum cholesterol and a significant increase in serum triglycerides level.
Howes et al., examined the effect of clozapine on glucose control and insulin sensitivity. Glucose homeostasis was measured in nine female and 11 male patients with schizophrenia (mean age=30.5 years, SD=7.4) before clozapine treatment and after a mean of 2.5 months (SD=0.95) of clozapine treatment. They concluded that Clozapine impairs glucose control within 4 months of treatment, independent of changes in insulin sensitivity and body mass index. Recently the effect of clozapine and of haloperidol on electrical and secretory activity of pancreatic beta cells was studied: while at lower glucose concentrations, clozapine had little effect on membrane potential, at higher doses, it led to marked depolarization of the membrane potential, despite differing glucose concentrations.  Similarly clozapine was shown to increase basal insulin release, in contrast to conventional antipsychotics. 
Akathisia occurs even occasionally with clozapine.  Very rarely tardive dyskinesia has been reported in patient receiving clozapine.  Sachdev et al.,  reviewed the published case reports of clozapine-induced neuroleptic malignant syndrome (NMS) and suggested that typical NMS does occur with clozapine and that its incidence may be as common as with the classic neuroleptics. The features of clozapine-induced NMS may be somewhat different, with fewer extrapyramidal side effects and a lower rise in creatine kinase levels. Atypical antipsychotic including clozapine are sometime associated with an atypical, but potentially lethal, neuroleptic malignant-like syndrome that is marked by fever and delirium without muscle rigidity. 
Cohen et al.,  conducted a study to examine the arrythmogenic effects of neuroleptics. Heart rate analysis was carried out in patients with schizophrenia on standard doses of neuroleptic monotherapy - 21 were on clozapine, 18 on haloperidol and 17 on olanzapine - and in 53 healthy subjects. They found that the patients with schizophrenia on clozapine had significantly higher heart rate, lower heart rate variability and lower high-frequency and higher low-frequency components compared with patients on haloperidol or olanzapine and matched control subjects and showed autonomic dysregulation and cardiac repolarisation changes. There have been isolated reports of paradoxical hypertension with clozapine use. , Myocarditis is a rare and potentially life-threatening complication of clozapine. There are reports of reversible myocarditis during treatment with clozapine for chronic resistant schizophrenia. The patient recovered rapidly on withdrawal of clozapine and with supportive management.  There is also report of clozapine-induced cardiac failure. 
Clozapine is known to increase seizure frequency. In a review  seizure frequency is calculated to be 1% at a dose less than 300 mg/day, 2.7% at 300 to 599 mg and 4.4% with dose 600 mg or more daily. Valproate is recommended as the standard therapy for the treatment of clozapine-induced seizures.  Gabapentin is also used as an alternative. , There is also report of successful use of Topiramate for the treatment of clozapine-induced seizures. 
Clozapine specifically has two important risks of intestinal dysfunction: potentially severe ileus  and sialorrhea, which may be related to deficient pharyngeal-esophageal clearing mechanisms most noticeable during sleep.  Sialorrhea begins early in treatment and most evident in night. Hypersalivation has been reported  to occur in about 54% patient receiving clozapine.
De novo emergence or exacerbation of obsessive-compulsive (OC) symptoms during treatment with clozapine has been described in the literature. Lykouras et al.,  reviewed the reported cases (30 case reports) and discussed the possible pathogenetic mechanisms involved in their occurrence. He concluded that a temporal relationship between the drug and the symptoms can not be established in the cases receiving clozapine and current data are insufficient to suggest a pattern. There are some reports from India also. 
Toxic delirium can occur in about 3% of patient.  Clozapine rarely induces allergic complications.  There is also evidence that clozapine may be associated with fatal thromboembolism,  acute interstitial nephritis  and pancreatic. 
Data regarding the potential teratogenacity of clozapine are not unanimous. There are some reports of congenital malformations and other complications during pregnancy. But there is report  of successful use of clozapine in pregnant woman with treatment-resistant schizophrenia.
| Conclusion|| |
The ten years of clinical experience of clozapine use in the dose range 100-400 mg/day as monotherapy or augmentation has been significantly safe and acceptable at large by patient subgroups. The side effect profile remained comparable to other SGA's, as evident from the unpublished data of the ongoing study at psychiatry center, SMS medical college, jaipur.
The result of the different studies indicated that clozapine exhibit superiority over typical antipsychotics in terms of both efficacy (as shown by an improvement in overall psychopathology) and safety. However the magnitude of its effect is not consistent. Efficacy data for other SGA's in the treatment of refractory schizophrenics were inconclusive.
So there is growing need to consider different treatment strategies. Whether monotherapy or adjuvant therapy for non responsive or partially responsive schizophrenics.
| References|| |
|1.||Hippius H. The founding of the CINP and the discovery of clozapine. In: Healy D, editor. The psychopharmacologists. Chapman and Hall: New York, NY; 1996. p. 185-213. |
|2.||Shen WW. Pharmacotherapy of schizophrenia: The American current status. Keio J Med 1994;43:192-200. |
|3.||Hippius H. The history of clozapine. Psychopharmacology 1989;99:S3-5. |
|4.||Gross H, Langner E. Effect profile of a chemically new broad spectrum neuroleptic of the dibenzo-diazepine group. Wien Med Wochenschr 1966;116:814-6. |
|5.||Bente D, Engelmeier M-P, Heinrich K, Schmitt W, Hippius H. Clinical studies with a neuroleptically active dibenzothiazepine derivative. Arzneimittelforschung 1966;16:314-6. |
|6.||Angst J, Jaenicke U, Padrutt A, Scharfetter C. Ergebnisse eines Doppelblindversuches von HF 1854 -Chlor- 11--methyl- 1-piperazinyl)-5H-dibenzo (b, e), diazepin) im Vergleich zu Levomepromazin. Pharrnackopsychiatrie 1971;4:192-200. |
|7.||Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic: A double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96. |
|8.||Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, et al . Equivalent Occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics. Am J Psychiatry 2004;161:1620-5. |
|9.||Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of Clozapine's effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9. |
|10.||Chakos M, Liberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second generation antipsychotics in patients with treatment resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26. |
|11.||Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomized trials. Schizophr Res 2002;56:1-10. |
|12.||Moncrieff J. Clozapine v Conventional antipsychotic drugs for treatment-resistant schizophrenia: A re-examination. Br J Psychiatry 2003;183:161-6. |
|13.||Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14:409-18. |
|14.||Agarwal AK, Sharma M, Srivastava S. An open clinical trial with clozapine in treatment resistant schizophrenics. Indian J Psychiatry 1997;39:70-5. |
|15.||Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Pollack S, et al . Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry 1994;35:278-80. |
|16.||Hector RI. The use of clozapine in the treatment of aggressive schizophrenia. Can J Psychiatry 1998;43:466-72. |
|17.||Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harv Rev Psychiatry 1995;3:1-9. |
|18.||Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90. |
|19.||Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003;160:1514-6. |
|20.||Ross DE. Clozapine and typical antipsychotics. Am J Psychiatry 2004;161:1925-6. |
|21.||Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9. |
|22.||Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 1980;137:16-21. |
|23.||Perkin DO. Clinical trials in schizophrenia with results for the real world. CNS Spectr 2006;11:9-13. |
|24.||McEvoy JP, Liberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al . Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patient with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10. |
|25.||Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al . The national institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31. |
|26.||Liberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al . effectiveness of antipsychotic drugs in patient with chronic schizophrenia. N Engl J Med 2005;353:1209-23. |
|27.||Lewis SW, Barness TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al . Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-23. |
|28.||Azorin JM, Spiegel R, Remington G, Vanelle JM, Pιrι JJ, Giguere M, et al . A Double-blind comparative study of Clozapine and Risperidone in the management of severe chronic Schizophrenia. Am J Psychiatry 2001;158:1305-13. |
|29.||Buckley PF. New dimension in the pharmacological treatment of schizophrenia and related psychosis. J Clin Pharmacol 1997;37:363-78. |
|30.||Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, et al . overt aggression and psychotic symptom in patient with schizophrenia treated with clozapine. J Clin Psychopharmacol 2004;24:225-8. |
|31.||McGurk SR, Carter C, Goldman R, Green MF, Marder SR, Xie H, et al . The effects of Clozapine and Risperidone on spatial working memory in schizophrenia. Am J Psychiatry 2005;162:1013-6. |
|32.||Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al . Neurocognitive effects of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28. |
|33.||Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res 2001;48:57-67. |
|34.||Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J. When symptoms persist: Clozapine augmentation strategies. Schizophr Bull 2001;27:615-28. |
|35.||Horner WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al . Clozapine versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82. |
|36.||Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, et al . A double blind controlled study of adjunctive treatment with risperidone in schizophrenic patient partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry 2005;66:63-72. |
|37.||Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM, et al . Amisulpride augmentation of clozapine: An open non- randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004;110:292-8. |
|38.||Agelink MW, Kauk, Ak L. clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004;161:924-25. |
|39.||Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, et al . An exploratory open label trial of aripiprazol as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-7. |
|40.||Rajarethinam R, Gilani S, Tancer M, DeQuardo J. Augmentation of clozapine partial responders with conventional antipsychotics. Schizophr Res 2003;60:97-8. |
|41.||Mowerman S, Siris SG. Adjuvant loxapine in a clozapine resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-7. |
|42.||Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998;10:113-5. |
|43.||Friedman J, Ault K, Powchik P. Pimozide augmentation for treatment of schizophrenic patients who are partial responder to clozapine. Biol Psychiatry 1997;42:522-3. |
|44.||Kaye NS. Ziprasidone augmentation of clozapine in 11 patient. J Clin Psychiatry 2003;64:15-6. |
|45.||Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine resistant schizophrenia. CNS Drugs 2005;19:843-72. |
|46.||Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Oliι JP, et al . Augmentation strategies of clozapine with antipsychotics in the treatment of ultra resistant schizophrenia. Clin Neuropharmacol 2006;29:28-33. |
|47.||Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10. |
|48.||Meltzer HY, Alphas L, Green AL, Altamura AC, Anand R, Bertoldi A, et al . clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91. |
|49.||Turetz M, Mozes T, Toren P, Chernauzan N, Yoran-Hegesh R, Mester R, et al . An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 1997;170:507-10. |
|50.||Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, et al . Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000;157:982-6. |
|51.||Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, et al . Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-64. |
|52.||Dassa D, Kaladjian A, Azorin JM, Giudicelli S. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993;163:822-4. |
|53.||Menza MM, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patient with Parkinson's disease. Ann Clin Psychiatry 1999;11:141-4. |
|54.||Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis, 5- year follow up review. Clin Neuropharmacol 2003;26:8-11. |
|55.||Chung C, Remington G. Predictors and markers of clozapine response. Psychopharmacology (Berl) 2005;179:317-25. |
|56.||Hoffbrand AV. Mechanism of clozapine induced agranulocytosis. Drug Saf 1992;79:1-60. |
|57.||Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006;188:255-63. |
|58.||Wetterling T. Bodyweight gain with atypical antipsychotics: A comparative review. Drug Safety 2001;24:59-73. |
|59.||Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al . Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975-81. |
|60.||Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, Pilowsky LS. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004;161:361-3. |
|61.||Best L, Yates AP, Reynolds GP. Actions of antipsychotic drugs on pancreatic beta cell function: Contrasting effects of clozapine and haloperidol. J Psychopharmacol 2005;19:597-601. |
|62.||Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro . Eur Neuropsychopharmacol 2004;14:115-9. |
|63.||Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45. |
|64.||Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Dose clozapine causes tardive dyskinesia? J Clin Psychiatry 1993;54:327-30. |
|65.||Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine induced neuroleptic malignant syndrome: A review and report of new cases. J Clin Psychopharmacol 1995;15:365-71. |
|66.||Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003;2:21-35. |
|67.||Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Br J Psychiatry 2001;179:167-71. |
|68.||Gupta S. Paradoxical hypertension associated with clozapine. Am J Psychiatry 1994;151:148. |
|69.||Parker RM. Paradoxical hypertension associated with clozapine. Med J Aust 1997;166:278. |
|70.||Kirpekar VC, Deshpande SM, Joshi PP. Reversible myocarditis in a patient receiving clozapine. Indian Heart J 2001;53:779-81. |
|71.||Thomas Kuruvilla, Sr Susan, Jayaprakash KK. Clozapine-induced cardiac failure. Indian J Psychiatry 2006;48:128-9. |
|72.||Devinsky O, Honigfeld G, Patin J. Clozapine related seizures. Neurology 1991;41:369-71. |
|73.||Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994;55:153-6. |
|74.||Usiskin SI, Nicolson R, Lenane M, Rapoport JL. Gabapentin prophylaxis of clozapine-induced seizures. Am J Psychiatry 2000;157:482-3. |
|75.||Landry P. Gabapentin for clozapine-related seizures. Am J Psychiatry 2001;158:1930-1. |
|76.||Navarro V, Pons A, Romero A, Bernardo M. Topiramate for clozapine-induced seizures. Am J Psychiatry 2001;158:968-9. |
|77.||Thιret L, Germain ML, Burde A. Current aspects of clozapine in the chalons-sur-marne psychiatric hospital: Intestinal obstruction with clozapine. Ann Med Psycho (Paris) 1995;153:474-7. |
|78.||Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: A pilot study. Biol Psychiatry 1996:40:1132-4. |
|79.||Dayvdov L, Botts SR. clozapine induced hypersalivation. Ann Pharmacother 2000;34:662-5. |
|80.||Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics: A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:333-46. |
|81.||Agarwal AK, Khalid A. Obsessive-compulsive symptoms during clozapine treatment. Indian J Psychiatry 1997;39:259-61. |
|82.||Grohmann R. Adverse effect of clozapine. Psychopharmacology 1989;99:8101-4. |
|83.||Stoppe G, Müller P, Fuchs T, Rüther E. Life-threatening allergic reaction to clozapine. Br J Psychiatry 1992;161:259-61. |
|84.||Knudson JF, Kortepeter C, Dubitsky GM, Ahmad SR, Chen M. antipsychotic drugs and venous thromboembolism. Lancet 2000;356:252-3. |
|85.||Au AF, Luthra V, Stern R. Clozapine induced acute interstitial nephritis. Am J Psychiatry 2004;161:1501. |
|86.||Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: From the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003;23:1123-30. |
|87.||Sethi S. Clozapine in pregnancy. Indian J Psychiatry 2006;48:196-7. |
Ram K Solanki
D-840, Malviya Nagar, Jaipur
Source of Support: None, Conflict of Interest: None
|This article has been cited by|
||Clozapine and SCH 23390 prevent the spatial working memory disruption induced by Δ9-THC administration into the medial prefrontal cortex
| ||Lívia Carla de Melo Rodrigues, Catarine Lima Conti, Ester Miyuki Nakamura-Palacios |
| ||Brain Research. 2011; 1382: 230 |
|[VIEW] | [DOI]|
||Treatment effects of traditional Chinese medicines Suoquan Pill and Wuling Powder on clozapine-induced hypersalivation in patients with schizophrenia: study protocol of a randomized, placebo-controlled trial
| ||CC Hung |
| ||Journal of Chinese Integrative Medicine. 2011; 9(5): 495 |
|[VIEW] | [DOI]|